Intensive Care Medicine

, Volume 42, Issue 9, pp 1374–1386 | Cite as

Community-acquired pneumonia related to intracellular pathogens

  • Catia Cillóniz
  • Antoni Torres
  • Michael Niederman
  • Menno van der Eerden
  • James Chalmers
  • Tobias Welte
  • Francesco Blasi
Review

Abstract

Community-acquired pneumonia (CAP) is associated with high rates of morbidity and mortality worldwide; the annual incidence of CAP among adults in Europe has ranged from 1.5 to 1.7 per 1000 population. Intracellular bacteria are common causes of CAP. However, there is considerable variation in the reported incidence between countries and change over time. The intracellular pathogens that are well established as causes of pneumonia are Legionella pneumophila, Mycoplasma pneumoniae, Chlamydophila pneumoniae, Chlamydophila psittaci, and Coxiella burnetii. Since it is known that antibiotic treatment for severe CAP is empiric and includes coverage of typical and atypical pathogens, microbiological diagnosis bears an important relationship to prognosis of pneumonia. Factors such as adequacy of initial antibiotic or early de-escalation of therapy are important variables associated with outcomes, especially in severe cases. Intracellular pathogens sometimes appear to cause more severe disease with respiratory failure and multisystem dysfunction associated with fatal outcomes. The clinical relevance of intracellular pathogens in severe CAP has not been specifically investigated. We review the prevalence, general characteristics, and outcomes of severe CAP cases caused by intracellular pathogens.

Keywords

Community-acquired pneumonia Pneumonia Intracellular pathogens Etiology 

Notes

Compliance with ethical standards

Conflicts of interest

The authors have no potential conflict of interest.

References

  1. 1.
    File TM Jr, Marrie TJ (2010) Burden of community-acquired pneumonia in North American adults. Postgrad Med 122(2):130–141PubMedCrossRefGoogle Scholar
  2. 2.
    Niederman MS (2007) Recent advances in community-acquired pneumonia: inpatient and outpatient. Chest 131(4):1205–1215PubMedCrossRefGoogle Scholar
  3. 3.
    Ewig S, Woodhead M, Torres A (2011) Towards a sensible comprehension of severe community-acquired pneumonia. Intensive Care Med 37(2):214–223PubMedCrossRefGoogle Scholar
  4. 4.
    Blasi F (2004) Atypical pathogens and respiratory tract infections. Eur Respir J 24(1):171–181PubMedCrossRefGoogle Scholar
  5. 5.
    Cilloniz C, Ewig S, Polverino E et al (2012) Community-acquired pneumonia in outpatients: aetiology and outcomes. Eur Respir J 40(4):931–938PubMedCrossRefGoogle Scholar
  6. 6.
    Dumke R, Schnee C, Pletz MW et al (2015) Mycoplasma pneumoniae and Chlamydia spp. infection in community-acquired pneumonia, Germany, 2011–2012. Emerg Infect Dis 21(3):426–434PubMedCentralCrossRefPubMedGoogle Scholar
  7. 7.
    Marrie TJ, Costain N, La SB et al (2012) The role of atypical pathogens in community-acquired pneumonia. Semin Respir Crit Care Med 33(3):244–256PubMedCrossRefGoogle Scholar
  8. 8.
    Basarab M, Macrae MB, Curtis CM (2014) Atypical pneumonia. Curr Opin Pulm Med 20(3):247–251PubMedCrossRefGoogle Scholar
  9. 9.
    Brown RJ, Farlane-Smith L, Phillips S, Chalker VJ (2015) Detection of macrolide resistant Mycoplasma pneumoniae in England, September 2014 to September 2015. Euro Surveill 20(48):30078PubMedCrossRefGoogle Scholar
  10. 10.
    Li X, Atkinson TP, Hagood J, Makris C, Duffy LB, Waites KB (2009) Emerging macrolide resistance in Mycoplasma pneumoniae in children: detection and characterization of resistant isolates. Pediatr Infect Dis J 28(8):693–696PubMedCrossRefGoogle Scholar
  11. 11.
    Jain S, Self WH, Wunderink RG et al (2015) Community-acquired pneumonia requiring Hospitalization among US adults. N Engl J Med 373(5):415–427PubMedPubMedCentralCrossRefGoogle Scholar
  12. 12.
    Cilloniz C, Ewig S, Polverino E et al (2011) Microbial aetiology of community-acquired pneumonia and its relation to severity. Thorax 66(4):340–346PubMedCrossRefGoogle Scholar
  13. 13.
    Capelastegui A, Espana PP, Bilbao A et al (2012) Etiology of community-acquired pneumonia in a population-based study: link between etiology and patients characteristics, process-of-care, clinical evolution and outcomes. BMC Infect Dis 12:134PubMedPubMedCentralCrossRefGoogle Scholar
  14. 14.
    Liu KT, Yang KY, Lee YC, Perng RP (2007) Risk factor analysis of acute respiratory distress syndrome among hospitalized patients with Chlamydophila pneumoniae pneumonia. J Chin Med Assoc 70(8):318–323PubMedCrossRefGoogle Scholar
  15. 15.
    Viasus D, Di YS, Garcia-Vidal C et al (2013) Community-acquired Legionella pneumophila pneumonia: a single-center experience with 214 hospitalized sporadic cases over 15 years. Medicine (Baltimore) 92(1):51–60CrossRefGoogle Scholar
  16. 16.
    Arnold FW, Summersgill JT, Lajoie AS et al (2007) A worldwide perspective of atypical pathogens in community-acquired pneumonia. Am J Respir Crit Care Med 175(10):1086–1093PubMedCrossRefGoogle Scholar
  17. 17.
    Cameron RL, Pollock KG, Lindsay DS, Anderson E (2015) Comparison of Legionella longbeachae and Legionella pneumophila cases in Scotland; implications for diagnosis, treatment and public health response. J Med Microbiol 65(2):142–146Google Scholar
  18. 18.
    Yu VL, Plouffe JF, Pastoris MC et al (2002) Distribution of Legionella species and serogroups isolated by culture in patients with sporadic community-acquired legionellosis: an international collaborative survey. J Infect Dis 186(1):127–128PubMedCrossRefGoogle Scholar
  19. 19.
    Whiley H, Bentham R (2011) Legionella longbeachae and legionellosis. Emerg Infect Dis 17(4):579–583PubMedPubMedCentralCrossRefGoogle Scholar
  20. 20.
    Carratala J, Garcia-Vidal C (2010) An update on Legionella. Curr Opin Infect Dis 23(2):152–157PubMedCrossRefGoogle Scholar
  21. 21.
    European Centre for Disease Prevention and Control (2016) Legionnaires’ disease surveillance in Europe, 2014. ECDC, StockholmGoogle Scholar
  22. 22.
    Woodhead M (2002) Community-acquired pneumonia in Europe: causative pathogens and resistance patterns. Eur Respir J Suppl 36:20s–27sPubMedCrossRefGoogle Scholar
  23. 23.
    Marston BJ, Plouffe JF, File TM Jr et al (1997) Incidence of community-acquired pneumonia requiring hospitalization. Results of a population-based active surveillance Study in Ohio. The Community-Based Pneumonia Incidence Study Group. Arch Intern Med 157(15):1709–1718PubMedCrossRefGoogle Scholar
  24. 24.
    Welte T, Torres A, Nathwani D (2012) Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax 67(1):71–79PubMedCrossRefGoogle Scholar
  25. 25.
    Den Boer JW, Nijhof J, Friesema I (2006) Risk factors for sporadic community-acquired Legionnaires’ disease. A 3-year national case-control study. Public Health 120(6):566–571CrossRefGoogle Scholar
  26. 26.
    Lanternier F, Tubach F, Ravaud P et al (2013) Incidence and risk factors of Legionella pneumophila pneumonia during anti-tumor necrosis factor therapy: a prospective French study. Chest 144(3):990–998PubMedCrossRefGoogle Scholar
  27. 27.
    Farnham A, Alleyne L, Cimini D, Balter S (2014) Legionnaires’ disease incidence and risk factors, New York, New York, USA, 2002–2011. Emerg Infect Dis 20(11):1795–1802PubMedPubMedCentralCrossRefGoogle Scholar
  28. 28.
    Jacobson KL, Miceli MH, Tarrand JJ, Kontoyiannis DP (2008) Legionella pneumonia in cancer patients. Medicine (Baltimore) 87(3):152–159CrossRefGoogle Scholar
  29. 29.
    Pletz MW, Rohde G, Schutte H, Bals R, von Baum H, Welte T, CAPNETZ-Studiengruppe (2011) Epidemiology and aetiology of community-acquired pneumonia (CAP). Dtsch Med Wochenschr 136(15):775–780PubMedCrossRefGoogle Scholar
  30. 30.
    Lim WS, Baudouin SV, George RC et al (2009) BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax 64(Suppl 3):iii1–55PubMedCrossRefGoogle Scholar
  31. 31.
    Cilloniz C, Polverino E, Ewig S et al (2013) Impact of age and comorbidity on cause and outcome in community-acquired pneumonia. Chest 144(3):999–1007PubMedCrossRefGoogle Scholar
  32. 32.
    Niederman MS, Mandell LA, Anzueto A et al (2001) Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 163:1730–1754PubMedCrossRefGoogle Scholar
  33. 33.
    Miyashita N, Obase Y, Ouchi K et al (2007) Clinical features of severe Mycoplasma pneumoniae pneumonia in adults admitted to an intensive care unit. J Med Microbiol 56(Pt 12):1625–1629PubMedCrossRefGoogle Scholar
  34. 34.
    Izumikawa K, Izumikawa K, Takazono T et al (2014) Clinical features, risk factors and treatment of fulminant Mycoplasma pneumoniae pneumonia: a review of the Japanese literature. J Infect Chemother 20(3):181–185PubMedCrossRefGoogle Scholar
  35. 35.
    Ewig S, Torres A (2003) Is Chlamydia pneumoniae an important pathogen in patients with community-acquired pneumonia? Eur Respir J 21(5):741–742PubMedCrossRefGoogle Scholar
  36. 36.
    Chalmers JD, Rother C, Salih W, Ewig S (2014) Healthcare-associated pneumonia does not accurately identify potentially resistant pathogens: a systematic review and meta-analysis. Clin Infect Dis 58(3):330–339PubMedCrossRefGoogle Scholar
  37. 37.
    Lui G, Ip M, Lee N et al (2009) Role of ‘atypical pathogens’ among adult hospitalized patients with community-acquired pneumonia. Respirology 14(8):1098–1105PubMedCrossRefGoogle Scholar
  38. 38.
    Phares CR, Wangroongsarb P, Chantra S et al (2007) Epidemiology of severe pneumonia caused by Legionella longbeachae, Mycoplasma pneumoniae, and Chlamydia pneumoniae: 1-year, population-based surveillance for severe pneumonia in Thailand. Clin Infect Dis 45(12):e147–e155PubMedCrossRefGoogle Scholar
  39. 39.
    Petrovay F, Balla E (2008) Two fatal cases of psittacosis caused by Chlamydophila psittaci. J Med Microbiol 57(Pt 10):1296–1298PubMedCrossRefGoogle Scholar
  40. 40.
    Fischer N, Rohde H, Indenbirken D et al (2014) Rapid metagenomic diagnostics for suspected outbreak of severe pneumonia. Emerg Infect Dis 20(6):1072–1075PubMedPubMedCentralCrossRefGoogle Scholar
  41. 41.
    Haas LE, Tjan DH, Schouten MA, van Zanten AR (2006) Severe pneumonia from psittacosis in a bird-keeper. Ned Tijdschr Geneeskd 150(3):117–121PubMedGoogle Scholar
  42. 42.
    Gacouin A, Revest M, Letheulle J et al (2012) Distinctive features between community-acquired pneumonia (CAP) due to Chlamydophila psittaci and CAP due to Legionella pneumophila admitted to the intensive care unit (ICU). Eur J Clin Microbiol Infect Dis 31(10):2713–2718PubMedCrossRefGoogle Scholar
  43. 43.
    Knittler MR, Sachse K (2015) Chlamydia psittaci: update on an underestimated zoonotic agent. Pathog Dis 73(1):1–15PubMedGoogle Scholar
  44. 44.
    Marrie TJ, Raoult D (1997) Q fever–a review and issues for the next century. Int J Antimicrob Agents 8(3):145–161PubMedCrossRefGoogle Scholar
  45. 45.
    Pebody RG, Wall PG, Ryan MJ, Fairley C (1996) Epidemiological features of Coxiella burnetii infection in England and Wales: 1984 to 1994. Commun Dis Rep CDR Rev 6(9):R128–R132PubMedGoogle Scholar
  46. 46.
    Roest HI, Ruuls RC, Tilburg JJ et al (2011) Molecular epidemiology of Coxiella burnetii from ruminants in Q fever outbreak, the Netherlands. Emerg Infect Dis 17(4):668–675PubMedPubMedCentralCrossRefGoogle Scholar
  47. 47.
    Dijkstra F, van der Hoek W, Wijers N et al (2012) The 2007–2010 Q fever epidemic in the Netherlands: characteristics of notified acute Q fever patients and the association with dairy goat farming. FEMS Immunol Med Microbiol 64(1):3–12PubMedCrossRefGoogle Scholar
  48. 48.
    Dahlgren FS, Haberling DL, McQuiston JH (2015) Q fever is underestimated in the United States: a comparison of fatal Q fever cases from two national reporting systems. Am J Trop Med Hyg 92(2):244–246PubMedPubMedCentralCrossRefGoogle Scholar
  49. 49.
    Schack M, Sachse S, Rodel J et al (2014) Coxiella burnetii (Q fever) as a cause of community-acquired pneumonia during the warm season in Germany. Epidemiol Infect 142(9):1905–1910PubMedCrossRefGoogle Scholar
  50. 50.
    Schimmer B, Ter SR, Wegdam M et al (2010) The use of a geographic information system to identify a dairy goat farm as the most likely source of an urban Q-fever outbreak. BMC Infect Dis 10:69PubMedPubMedCentralCrossRefGoogle Scholar
  51. 51.
    Wielders CC, Wuister AM, de Visser V et al (2014) Characteristics of hospitalized acute Q fever patients during a large epidemic, the Netherlands. PLoS One 9(3):e91764PubMedPubMedCentralCrossRefGoogle Scholar
  52. 52.
    Hartzell JD, Wood-Morris RN, Martinez LJ, Trotta RF (2008) Q fever: epidemiology, diagnosis, and treatment. Mayo Clin Proc 83(5):574–579PubMedCrossRefGoogle Scholar
  53. 53.
    Cilloniz C, Ewig S, Ferrer M et al (2011) Community-acquired polymicrobial pneumonia in the intensive care unit: aetiology and prognosis. Crit Care 15(5):R209PubMedPubMedCentralCrossRefGoogle Scholar
  54. 54.
    Correia AM, Ferreira JS, Borges V et al (2016) Probable person-to-person transmission of Legionnaires’ disease. N Engl J Med 374(5):497–498PubMedCrossRefGoogle Scholar
  55. 55.
    Nilsson AC, Bjorkman P, Welinder-Olsson C, Widell A, Persson K (2010) Clinical severity of Mycoplasma pneumoniae (MP) infection is associated with bacterial load in oropharyngeal secretions but not with MP genotype. BMC Infect Dis 10:39PubMedPubMedCentralCrossRefGoogle Scholar
  56. 56.
    Jiang W, Qian L, Liang H, Tian M, Liu F, Zhao D (2014) Relationships between the varied ciliated respiratory epithelium abnormalities and severity of Mycoplasma pneumoniae pneumonia. Scand J Infect Dis 46(7):486–492PubMedCrossRefGoogle Scholar
  57. 57.
    Kannan TR, Provenzano D, Wright JR, Baseman JB (2005) Identification and characterization of human surfactant protein A binding protein of Mycoplasma pneumoniae. Infect Immun 73(5):2828–2834PubMedPubMedCentralCrossRefGoogle Scholar
  58. 58.
    Hanada S, Morozumi M, Takahashi Y et al (2014) Community-acquired pneumonia caused by macrolide-resistant Mycoplasma pneumoniae in adults. Intern Med 53(15):1675–1678PubMedCrossRefGoogle Scholar
  59. 59.
    Miyashita N, Maruyama T, Kobayashi T et al (2011) Community-acquired macrolide-resistant Mycoplasma pneumoniae pneumonia in patients more than 18 years of age. J Infect Chemother 17(1):114–118PubMedCrossRefGoogle Scholar
  60. 60.
    Cao B, Zhao CJ, Yin YD et al (2010) High prevalence of macrolide resistance in Mycoplasma pneumoniae isolates from adult and adolescent patients with respiratory tract infection in China. Clin Infect Dis 51(2):189–194PubMedCrossRefGoogle Scholar
  61. 61.
    Waites KB, Talkington DF (2004) Mycoplasma pneumoniae and its role as a human pathogen. Clin Microbiol Rev 17(4):697–728PubMedPubMedCentralCrossRefGoogle Scholar
  62. 62.
    Narita M (2010) Pathogenesis of extrapulmonary manifestations of Mycoplasma pneumoniae infection with special reference to pneumonia. J Infect Chemother 16(3):162–169PubMedCrossRefGoogle Scholar
  63. 63.
    Tanaka H, Narita M, Teramoto S et al (2002) Role of interleukin-18 and T-helper type 1 cytokines in the development of Mycoplasma pneumoniae pneumonia in adults. Chest 121(5):1493–1497PubMedCrossRefGoogle Scholar
  64. 64.
    Marrie TJ, Peeling RW, Reid T, De CE (2003) Chlamydia species as a cause of community-acquired pneumonia in Canada. Eur Respir J 21(5):779–784PubMedCrossRefGoogle Scholar
  65. 65.
    Kern JM, Maass V, Maass M (2009) Molecular pathogenesis of chronic Chlamydia pneumoniae infection: a brief overview. Clin Microbiol Infect 15(1):36–41PubMedCrossRefGoogle Scholar
  66. 66.
    Dupuis G, Petite J, Peter O, Vouilloz M (1987) An important outbreak of human Q fever in a Swiss Alpine valley. Int J Epidemiol 16(2):282–287PubMedCrossRefGoogle Scholar
  67. 67.
    Marrie TJ (1990) Q fever–a review. Can Vet J 31(8):555–563PubMedPubMedCentralGoogle Scholar
  68. 68.
    Hackstadt T, Williams JC (1981) Biochemical stratagem for obligate parasitism of eukaryotic cells by Coxiella burnetii. Proc Natl Acad Sci USA 78(5):3240–3244PubMedPubMedCentralCrossRefGoogle Scholar
  69. 69.
    Haubitz S, Hitz F, Graedel L et al (2014) Ruling out Legionella in community-acquired pneumonia. Am J Med 127(10):1010–1019PubMedCrossRefGoogle Scholar
  70. 70.
    File TM (2009) The science of selecting antimicrobials for community-acquired pneumonia (CAP). J Manag Care Pharm 15(2 Suppl):S5–S11PubMedGoogle Scholar
  71. 71.
    Atkinson TP, Balish MF, Waites KB (2008) Epidemiology, clinical manifestations, pathogenesis and laboratory detection of Mycoplasma pneumoniae infections. FEMS Microbiol Rev 32(6):956–973PubMedCrossRefGoogle Scholar
  72. 72.
    Sakai T, Ishida T, Arita M et al (2015) A study on the clinical course and antimicrobial susceptibility of Mycoplasma pneumoniae in a community hospital. Kansenshogaku Zasshi 89(4):458–464PubMedGoogle Scholar
  73. 73.
    Principi N, Esposito S (2013) Macrolide-resistant Mycoplasma pneumoniae: its role in respiratory infection. J Antimicrob Chemother 68(3):506–511PubMedCrossRefGoogle Scholar
  74. 74.
    Blasi F, Tarsia P, Aliberti S (2009) Chlamydophila pneumoniae. Clin Microbiol Infect 15(1):29–35PubMedCrossRefGoogle Scholar
  75. 75.
    CDC (2010) Case definitions for infectious conditions under public health surveillance. National Notifiable Diseases Surveillance System, CDCGoogle Scholar
  76. 76.
    Marrie TJ (2004) Q fever pneumonia. Curr Opin Infect Dis 17(2):137–142PubMedCrossRefGoogle Scholar
  77. 77.
    Jarraud S, Descours G, Ginevra C, Lina G, Etienne J (2013) Identification of legionella in clinical samples. Methods Mol Biol 954:27–56PubMedCrossRefGoogle Scholar
  78. 78.
    Cloud JL, Carroll KC, Pixton P, Erali M, Hillyard DR (2000) Detection of Legionella species in respiratory specimens using PCR with sequencing confirmation. J Clin Microbiol 38(5):1709–1712PubMedPubMedCentralGoogle Scholar
  79. 79.
    Marrero M, Raoult D (1989) Centrifugation-shell vial technique for rapid detection of Mediterranean spotted fever rickettsia in blood culture. Am J Trop Med Hyg 40(2):197–199PubMedGoogle Scholar
  80. 80.
    Shimada T, Noguchi Y, Jackson JL et al (2009) Systematic review and metaanalysis: urinary antigen tests for Legionellosis. Chest 136(6):1576–1585PubMedCrossRefGoogle Scholar
  81. 81.
    Welti M, Jaton K, Altwegg M, Sahli R, Wenger A, Bille J (2003) Development of a multiplex real-time quantitative PCR assay to detect Chlamydia pneumoniae, Legionella pneumophila and Mycoplasma pneumoniae in respiratory tract secretions. Diagn Microbiol Infect Dis 45(2):85–95PubMedCrossRefGoogle Scholar
  82. 82.
    Stralin K, Backman A, Holmberg H, Fredlund H, Olcen P (2005) Design of a multiplex PCR for Streptococcus pneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae and Chlamydophila pneumoniae to be used on sputum samples. APMIS 113(2):99–111PubMedCrossRefGoogle Scholar
  83. 83.
    Nomanpour B, Ghodousi A, Babaei T, Jafari S, Feizabadi MM (2012) Single tube real time PCR for detection of Streptococcus pneumoniae, Mycoplasma pneumoniae, Chlamydophila pneumoniae and Legionella pneumophila from clinical samples of CAP. Acta Microbiol Immunol Hung 59(2):171–184PubMedCrossRefGoogle Scholar
  84. 84.
    Potts A, Donaghy M, Marley M et al (2013) Cluster of Legionnaires disease cases caused by Legionella longbeachae serogroup 1, Scotland, August to September 2013. Euro Surveill 18(50):20656PubMedCrossRefGoogle Scholar
  85. 85.
    Fenollar F, Raoult D (2004) Molecular genetic methods for the diagnosis of fastidious microorganisms. APMIS 112(11–12):785–807PubMedCrossRefGoogle Scholar
  86. 86.
    Dunbar LM, Khashab MM, Kahn JB, Zadeikis N, Xiang JX, Tennenberg AM (2004) Efficacy of 750-mg, 5-day levofloxacin in the treatment of community-acquired pneumonia caused by atypical pathogens. Curr Med Res Opin 20(4):555–563PubMedCrossRefGoogle Scholar
  87. 87.
    Garau J, Fritsch A, Arvis P, Read RC (2010) Clinical efficacy of moxifloxacin versus comparator therapies for community-acquired pneumonia caused by Legionella spp. J Chemother 22(4):264–266PubMedCrossRefGoogle Scholar
  88. 88.
    Dunbar LM, Farrell DJ (2007) Activity of telithromycin and comparators against isolates of Legionella pneumophila collected from patients with community-acquired respiratory tract infections: PROTEKT years 1–5. Clin Microbiol Infect 13(7):743–746PubMedCrossRefGoogle Scholar
  89. 89.
    Blazquez Garrido RM, Espinosa Parra FJ, Alemany FL et al (2005) Antimicrobial chemotherapy for Legionnaires disease: levofloxacin versus macrolides. Clin Infect Dis 40(6):800–806PubMedCrossRefGoogle Scholar
  90. 90.
    Bartlett JG, Dowell SF, Mandell LA, File TM Jr, Musher DM, Fine MJ (2000) Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America. Clin Infect Dis 31(2):347–382PubMedCrossRefGoogle Scholar
  91. 91.
    Waites KB, Crabb DM, Duffy LB (2003) Inhibitory and bactericidal activities of gemifloxacin and other antimicrobials against Mycoplasma pneumoniae. Int J Antimicrob Agents 21(6):574–577PubMedCrossRefGoogle Scholar
  92. 92.
    Bebear CM, Renaudin H, Bryskier A, Bebear C (2000) Comparative activities of telithromycin (HMR 3647), levofloxacin, and other antimicrobial agents against human mycoplasmas. Antimicrob Agents Chemother 44(7):1980–1982PubMedPubMedCentralCrossRefGoogle Scholar
  93. 93.
    Miyashita N, Kawai Y, Inamura N et al (2015) Setting a standard for the initiation of steroid therapy in refractory or severe Mycoplasma pneumoniae pneumonia in adolescents and adults. J Infect Chemother 21(3):153–160PubMedCrossRefGoogle Scholar
  94. 94.
    Radisic M, Torn A, Gutierrez P, Defranchi HA, Pardo P (2000) Severe acute lung injury caused by Mycoplasma pneumoniae: potential role for steroid pulses in treatment. Clin Infect Dis 31(6):1507–1511PubMedCrossRefGoogle Scholar
  95. 95.
    Tamura A, Matsubara K, Tanaka T, Nigami H, Yura K, Fukaya T (2008) Methylprednisolone pulse therapy for refractory Mycoplasma pneumoniae pneumonia in children. J Infect 57(3):223–228PubMedCrossRefGoogle Scholar
  96. 96.
    Sobradillo V, Zalacain R, Capelastegui A, Uresandi F, Corral J (1992) Antibiotic treatment in pneumonia due to Q fever. Thorax 47(4):276–278PubMedPubMedCentralCrossRefGoogle Scholar
  97. 97.
    Teunis PF, Schimmer B, Notermans DW et al (2013) Time-course of antibody responses against Coxiella burnetii following acute Q fever. Epidemiol Infect 141(1):62–73PubMedCrossRefGoogle Scholar
  98. 98.
    Anderson A, Bijlmer H, Fournier PE et al (2013) Diagnosis and management of Q fever–United States, 2013: recommendations from CDC and the Q Fever Working Group. MMWR Recomm Rep 62(RR-03):1–30PubMedGoogle Scholar
  99. 99.
    Jain S, Self WH, Wunderink RG et al (2015) Community-acquired pneumonia requiring Hospitalization among US adults. N Engl J Med 373(5):415–427PubMedPubMedCentralCrossRefGoogle Scholar
  100. 100.
    Herrera M, Aguilar YA, Rueda ZV, Muskus C, Velez LA (2016) Comparison of serological methods with PCR-based methods for the diagnosis of community-acquired pneumonia caused by atypical bacteria. J Negat Results Biomed 15(1):3PubMedPubMedCentralCrossRefGoogle Scholar
  101. 101.
    Thurman KA, Warner AK, Cowart KC, Benitez AJ, Winchell JM (2011) Detection of Mycoplasma pneumoniae, Chlamydia pneumoniae, and Legionella spp. in clinical specimens using a single-tube multiplex real-time PCR assay. Diagn Microbiol Infect Dis 70(1):1–9PubMedCrossRefGoogle Scholar
  102. 102.
    Qu J, Gu L, Wu J et al (2013) Accuracy of IgM antibody testing, FQ-PCR and culture in laboratory diagnosis of acute infection by Mycoplasma pneumoniae in adults and adolescents with community-acquired pneumonia. BMC Infect Dis 13:172PubMedPubMedCentralCrossRefGoogle Scholar
  103. 103.
    Mandell LA, Wunderink RG, Anzueto A et al (2007) Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 1(44 Suppl 2):S27–S72CrossRefGoogle Scholar
  104. 104.
    Murdoch DR, Podmore RG, Anderson TP et al (2013) Impact of routine systematic polymerase chain reaction testing on case finding for Legionnaires’ disease: a pre-post comparison study. Clin Infect Dis 57(9):1275–1281PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg and ESICM 2016

Authors and Affiliations

  • Catia Cillóniz
    • 1
  • Antoni Torres
    • 1
  • Michael Niederman
    • 2
  • Menno van der Eerden
    • 3
  • James Chalmers
    • 4
    • 5
  • Tobias Welte
    • 6
  • Francesco Blasi
    • 7
  1. 1.Department of Pneumology, Institut Clinic del Tórax, Hospital Clinic of Barcelona Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)University of Barcelona (UB)—SGR 911—Ciber de Enfermedades Respiratorias (Ciberes)BarcelonaSpain
  2. 2.Division of Pulmonary and Critical Care MedicineWeill Cornell MedicineNew YorkUSA
  3. 3.Department of Pulmonary diseasesErasmus Medical CentreRotterdamThe Netherlands
  4. 4.Scottish Centre for Respiratory ResearchUniversity of DundeeDundeeUK
  5. 5.Ninewells Hospital and Medical SchoolDundeeUK
  6. 6.Department of Pulmonary MedicineHannover Medical School and Member of the German Center of Lung Research (DZL)HannoverGermany
  7. 7.Department of Pathophysiology and TransplantationUniversità degli Studi di Milano, IRCCS Fondazione Ospedale Maggiore Policlinico Cà GrandaMilanItaly

Personalised recommendations